Please login to the form below
mongersen
This page shows the latest mongersen news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more
The company’s psoriasis drug Otezla is also underperforming, and another blockbuster candidate mongersen failed in phase III.
Latest news
-
Celgene pays $300m upfront for immunology start-up Delinia
other pipeline candidates in this therapeutic category including mongersen for inflammatory bowel disease and ozanimod for multiple sclerosis which are both in late-stage testing.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Grace Communications
We’re an independent healthcare brand communications agency with a host of awards that speak to our success. Combining razor-sharp insights...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
